1. bookVolumen 72 (2022): Edición 3 (September 2022)
Detalles de la revista
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
access type Acceso abierto

The effectiveness of dexamethasone as a combination therapy for COVID-19

Publicado en línea: 13 Apr 2022
Volumen & Edición: Volumen 72 (2022) - Edición 3 (September 2022)
Páginas: 345 - 358
Aceptado: 28 Jan 2022
Detalles de la revista
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año

Coronavirus disease 2019 (COVID-19) was reported as a global pandemic in March 2020 after invading many countries and leaving behind tens of thousands of infected patients in a brief time span. Approval of a few vaccines has been obtained and their efficacy of varying degrees established. Still, there is no effective pharmaceutical agent for the treatment of COVID-19 though several drugs are undergoing clinical trials. Recent studies have shown that dexamethasone, a corticosteroid, can reduce the rate of COVID-19-related mortality in the intensive care unit by 35 % for patients who are on mechanical ventilation. Although variable efficacy of other combination therapies has been reported for treating COVID-19 associated with acute respiratory distress syndrome (ARDS), dexamethasone is an extensively used drug in many treatment regimens against COVID-19. The current review aims to explore the role of dexamethasone as an efficient combination treatment for COVID-19.


1. Y. Shang, C. Pan, X. Yang, M. Zhong, X. Shang, Z. Wu, Z. Yu, W. Zhang, Q. Zhong and X. Zheng, L. Sang, L. Jiang, J. Zhang, W. Xiong, J. Liu and D. Chen, Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China, Ann. Intensive Care 10(1) (2020) Article ID 73 (24 pages); https://doi.org/10.1186/s13613-020-00689-110.1186/s13613-020-00689-1727565732506258 Search in Google Scholar

2. P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P. D. Kwong, B. S. Graham, J. R. Mascola, J. Y. Chang, M. T. Yin, M. Sobieszczyk, C. A. Kyratsous, L. Shapiro, Z. Sheng, Y. Huang and D. D. Ho, Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1.7, Nature 593 (2021) 130–135; https://doi.org/10.1038/s41586-021-03398-210.1038/s41586-021-03398-233684923 Search in Google Scholar

3. S. Su, G. Wong, W. Shi, J. Liu, A. K. Lai, J. Zhou, W. Liu, Y. Bi and G .F. Gao, Epidemiology, genetic recombination, and pathogenesis of coronaviruses, Trends Microbiol. 24(6) (2016) 490–502; https://doi.org/10.1016/j.tim.2016.03.00310.1016/j.tim.2016.03.003712551127012512 Search in Google Scholar

4. K. Liu, Y.-Y. Fang, Y. Deng, W. Liu, M.-F. Wang, J.-P. Ma, W. Xiao, Y.-N. Wang, M.-H. Zhong, C.-H. Li, G.-C. Li and H.-G. Liu, Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province, Chin. Med. J. 133(9) (2020) 1025–1031; https://doi.org/10.1097/CM9.000000000000074410.1097/CM9.0000000000000744714727732044814 Search in Google Scholar

5. C. W. K. Lam, M. H. M. Chan and C. K. Wong, Severe acute respiratory syndrome: Clinical and laboratory manifestations, Clin. Biochem. Rev. 25(2) (2004) 121–132. Search in Google Scholar

6. S. Lu, Q. Zhou, L. Huang, Q. Shi, S. Zhao, Z. Wang, W. Li, Y. Tang, Y. Ma, X. Luo, T. Fukuoka, H. S. Ahn, M. S. Lee, Z. Luo, E. Liu, Y. Chen, C. Zhou and D. Peng (on behalf of COVID-19 Evidence and Recommendations Working Group), Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis, Ann. Transl. Med. 8(10) (2020) Article ID 627 (21 pages); https://doi.org/10.21037/atm-20-330710.21037/atm-20-3307729062832566564 Search in Google Scholar

7. M. Merad and J. C. Martin, Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages, Nat. Rev. Immunol. 20 (2020) 355–362; https://doi.org/10.1038/s41577-020-0331-410.1038/s41577-020-0331-4720139532376901 Search in Google Scholar

8. M. Z. Tay, C. M. Poh, L. Rénia, P. A. MacAry and L. P. Ng, The trinity of COVID-19: immunity, inflamma tion and intervention, Nat. Rev. Immunol. 20 (2020) 363–374; https://doi.org/10.1038/s41577-020-0311-810.1038/s41577-020-0311-8718767232346093 Search in Google Scholar

9. A. G. Harriso, T. Lin and P. Wang, Mechanisms of SARS-CoV-2 transmission and pathogenesis, Trends Immunol. 41(12) (2020) 1100–1115; http://doi.org/10.1016/j.it.2020.10.00410.1016/j.it.2020.10.004755677933132005 Search in Google Scholar

10. X. Sun, T. Wang, D. Cai, Z. Hu, J. Chen, H. Liao, L. Zhi, H. Wei, Z. Zhang, Y. Qiu and J. Wang, Cytokine storm intervention in the early stages of COVID-19 pneumonia, Cytokine Growth Factor Rev. 53 (2020) 38–42; https://doi.org/10.1016/j.cytogfr.2020.04.00210.1016/j.cytogfr.2020.04.002718252732360420 Search in Google Scholar

11. Q. Ruan, K. Yang, W. Wang, L. Jiang and J. Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med. 46 (2020) 846–848; https://doi.org/10.1007/s00134-020-05991-x10.1007/s00134-020-05991-x708011632125452 Search in Google Scholar

12. K. Yuki, M. Fujiogi and S. Koutsogiannaki, COVID-19 pathophysiology: A review, Clin. Immunol. 215 (2020) Article ID 108427; https://doi.org/10.1016/j.clim.2020.10842710.1016/j.clim.2020.108427 Search in Google Scholar

13. X. Fang, Q. Mei, T. Yang, L. Li, Y. Wang, F. Tong, S. Geng and A. Pan, Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19, J. Infect. 81(1) (2020) 147–178; https://doi.10.1016/j.jinf.2020.03.039 Search in Google Scholar

14. V. Selvaraj, K. Dapaah-Afriyie, A. Finn and T. P. Flanigan, Short-term dexamethasone in Sars-CoV-2 patients, RI Med. J. 103 (2020) 39–43; https://doi.org/10.1101/2020.06.19.2010917310.1101/2020.06.19.20109173 Search in Google Scholar

15. P. Sinha, A. Mostaghim, C. G. Bielick, A. McLaughlin, D. H. Hamer, L. M. Wetzler, N. Bhadelia, M. A. Fagan, B. P. Linas, S. A. Assoumou, M. H. Ieong, N. H. Lin, E. R, Cooper, K. D. Brade, L. F. White, T. F. Barlam and M. Sagar, Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge, Int. J. Infect. Dis. 99 (2020) 28–33; https://doi.org/10.1016/j.ijid.2020.07.02310.1016/j.ijid.2020.07.023 Search in Google Scholar

16. D. Wu, Q. Rao and W. Zhang, The natural course of COVID-19 patients without clinical intervention, J. Med. Virol. 93 (2021) 5527–5537; https://doi.org/10.1002/jmv.2708710.1002/jmv.27087 Search in Google Scholar

17. C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang and B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395(10223) (2020) 497–506; https://doi.org/10.1016/S0140-6736(20)30183-510.1016/S0140-6736(20)30183-5 Search in Google Scholar

18. J. Phua, L. Weng, L. Ling, M. Egi, C. M. Lim, J. V. Divatia, B. R. Shrestha, Y. M. Arabi, J. Ng, C. D. Gomersall, M. Nishimura, Y. Koh and B. Du, Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations, Lancet Respir. Med. 8 (2020) 506–517; https://doi.org/10.1016/S2213-2600(20)30161-210.1016/S2213-2600(20)30161-2 Search in Google Scholar

19. Z. Xiang, J. Liu, D. Shi, W. Chen, J. Li, R. Yan, Y. Bi, W. Hu, Z. Zhu, Y. Yu and Z. Yang, Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels, Int. J. Biol. Sci. 16(13) (2020) 2382–2391; https://doi.org/10.7150/ijbs.4765210.7150/ijbs.47652 Search in Google Scholar

20. M. Lester, A. Sahin and A. Pasyar, The use of dexamethasone in the treatment of COVID-19, Ann. Med. Surg. (London) 56 (2020) 218–219; https://doi.org/10.1016/j.amsu.2020.07.00410.1016/j.amsu.2020.07.004 Search in Google Scholar

21. P. Horby, W. S. Lim, J. R. Emberson, M. Mafham, J. L. Bell, L. Linsell, N. Staplin, C. Brightling, A. Ustianowski, E. Elmahi, B. Prudon, C. Green, T. Felton, D. Chadwick, K. Rege, C. Fegan, L. C. Chappell, S. N. Faust, T. Jaki, K. Jeffery, A. Montgomery, K. Rowan, E. Juszczak, J. K. Baillie, R. Haynes, M. J. Landray (The RECOVERY Collaborative Group), Dexamethasone in hospitalized patients with Covid-19 – preliminary report, N. Engl. J. Med. 384(8) (2021) 693–704; https://doi.org/10.1056/NEJMoa202143610.1056/NEJMoa2021436 Search in Google Scholar

22. C. D. Russell, J. E. Millar and J. K. Baillie, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet 395 (2020) 473–475; https://doi.org/10.1016/S0140-6736(20)30317-210.1016/S0140-6736(20)30317-2 Search in Google Scholar

23. J. Villar, C. Ferrando, D. Martínez, A. Ambrós, T. Muñoz, J. A. Soler, G. Aguilar, F. Alba, E. González-Higueras, L. A. Conesa, C. Martín-Rodríguez, F. J. Díaz-Domínguez, P. Serna-Grande, R. Rivas, J. Ferreres, Javier Belda, L. Capilla, A. Tallet, J. M. Añón, R. L. Fernández and J. M. González-Martín, Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial, Lancet Respir. Med. 8 (2020) 267–276; https://doi.org/10.1016/S2213-2600(19)30417-510.1016/S2213-2600(19)30417-5 Search in Google Scholar

24. A. A. Ordonez, M. Maiga, S. Gupta, E. A. Weinstein, W. R. Bishai and S. K. Jain, Novel adjunctive therapies for the treatment of tuberculosis, Curr. Mol. Med. 14(3) (2014) 385–395; https://doi.org/10.2174/156652401366613111811243110.2174/1566524013666131118112431448477424236454 Search in Google Scholar

25. A. Grzanka, M. Misiołek, W. Golusiński and J. Jarząb, Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis, Eur. Arch. Oto-Rhino-Laryngol. 268 (2011) 247–253; https://doi.org/10.1007/s00405-010-1330-z10.1007/s00405-010-1330-z302118620628753 Search in Google Scholar

26. I. B. Mitre-Aguilar, A. J. Cabrera-Quintero and A. Zentella-Dehesa, Genomic and non-genomic effects of glucocorticoids: implications for breast cancer, Int. J. Clin. Exp. Pathol. 8(1) (2015) 1–10. Search in Google Scholar

27. M. Karn, S. Yonghang and S. Ghimire, Corticosteroids in COVID-19: We should be mindful of their acute toxicities, J. Clin. Pharmacol. 61(10) (2021) 1301–1302; https://doi.org/10.1002/jcph.193610.1002/jcph.1936842674534196415 Search in Google Scholar

28. S. S. Hasan, T. Capstick, R. Ahmed, C. S. Kow, F. Mazhar, H. A. Merchant and S. R. Zaidi, Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a syste matic review and meta-analysis, Expert Rev. Respir. Med. 14(11) (2020) 1149–1163; https://doi.org/10.1080/17476348.2020.180436510.1080/17476348.2020.1804365754496832734777 Search in Google Scholar

29. F. Chen, L. Hao, S. Zhu, X. Yang, W. Shi, K. Zheng, T. Wang and H. Chen, Potential adverse effects of dexamethasone therapy on COVID-19 patients: Review and recommendations, Infect. Dis. Ther. 10(4) (2021) 1907–1931; https://doi.org/10.1007/s40121-021-00500-z10.1007/s40121-021-00500-z829804434296386 Search in Google Scholar

30. R. Zhao, H. Wang, X. Wang and F. Feng, Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis, Osteoporos. Int. 28 (2017) 1027–1034; https://doi.org.10.1007/s00198-016-3824-z Search in Google Scholar

31. X. Li and X. Ma, Acute respiratory failure in COVID-19: is it “typical” ARDS? Crit. Care 24 (2020) Article ID 198 (5 pages); https://doi.org/10.1186/s13054-020-02911-910.1186/s13054-020-02911-9720279232375845 Search in Google Scholar

32. M. Yasir, A. Goyal, P. Bansal and S. Sonthalia, Corticosteroid Adverse Effects, in StatPearls [Internet], StatPearls Publishing, Treasure Island (FL, USA) 2022. Search in Google Scholar

33. L. Kornel, A. V. Prancan, N. Kanamarlapudi, J. Hynes and E. Kuzianik, Study on the mechanisms of glucocorticoid-induced hypertension: glucocorticoids increase transmembrane Ca2+ influx in vascular smooth muscle in vivo, Endocr. Res. 21(1–2) (1995) 203–210; https://doi.org/10.3109/0743580950903043610.3109/074358095090304367588382 Search in Google Scholar

34. K. Smets and P. Vanhaesebrouck, Dexamethasone associated systemic hypertension in low birth weight babies with chronic lung disease, Eur. J. Pediatr. 155 (1996) 573–575.10.1007/BF019579078831080 Search in Google Scholar

35. L. Berbegal, F. J. DeLeon and J. F. Silvestre, Hypersensitivity reactions to corticosteroids, Actas Dermo-Sifiliogr. (Engl.) 107(2) (2016) 107–115; https://doi.org/10.1016/j.adengl.2016.01.00310.1016/j.adengl.2016.01.003 Search in Google Scholar

36. J. E. Henriksen, F. Alford, G. M. Ward and H. Beck-Nielsen, Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients, Diabetologia 40 (1997) 1439–1448; https://doi.org/10.1007/s00125005084710.1007/s001250050847 Search in Google Scholar

37. G. F. Keenan, Management of complications of glucocorticoid therapy, Clin. Chest Med. 18(3) (1997) 507–520; https://doi.org/10.1016/S0272-5231(05)70398-110.1016/S0272-5231(05)70398-1 Search in Google Scholar

38. H. O. Conn and T. Poynard, Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy, J. Intern. Med. 236(6) (1994) 619–632; https://doi.org/10.1111/j.1365-2796.1994.tb00855.x10.1111/j.1365-2796.1994.tb00855.x7989897 Search in Google Scholar

39. N. K. Lee, S. Kim, S. B. Hong, S. J. Lee, T. U. Kim, H. Ryu, J. W. Lee, J. Y. Kim and H. B. Suh, CT diagnosis of non-traumatic gastrointestinal perforation: an emphasis on the causes, Jpn. J. Radiol. 38 (2020) 101–111; https://doi.org/10.1007/s11604-019-00910-710.1007/s11604-019-00910-731848888 Search in Google Scholar

40. P. C. Ng, K. G. Brownlee and P. R. Dear, Gastroduodenal perforation in preterm babies treated with dexamethasone for bronchopulmonary dysplasia, Arch. Dis. Child. 66 (1991) 1164–1166; https://doi.org/10.1136/adc.66.10_Spec_No.116410.1136/adc.66.10_Spec_No.116415902771750771 Search in Google Scholar

41. R. Alexanian, M. A. Dimopoulos, K. Delasalle and B. Barlogie, Primary dexamethasone treatment of multiple myeloma, Blood 80(4) (1992) 887–890; https://doi.org/10.1182/blood.V80.4.887.88710.1182/blood.V80.4.887.887 Search in Google Scholar

42. M. A. Kerachian, C. Séguin and E. J. Harvey, Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action, J. Steroid Biochem. Mol. Biol. 114(3) (2009) 121–128; https://doi.org/10.1016/j.jsbmb.2009.02.00710.1016/j.jsbmb.2009.02.007712623519429441 Search in Google Scholar

43. X. Wu, C. Geng, W. Sun and M. Tan, Incidence and risk factors of osteonecrosis of femoral head in multiple myeloma patients undergoing dexamethasone-based regimens, BioMed Res. Int. 2020 (2020) Article ID 7126982 (7 pages); https://doi.org/10.1155/2020/712698210.1155/2020/7126982724641132509867 Search in Google Scholar

44. N. K. Rahayu and A. Emily, Clinical profile of steroid-induced glaucoma in Bali Mandara Eye Hospital year 2019, Intisari Sains Medis 12(1) (2021) 6–8; https://doi.org/10.15562/ism.v12i1.872 Search in Google Scholar

45. G. S. Zode, A. B. Sharma, X. Lin, C. C. Searby, K. Bugge, G. H. Kim, A. F. Clark and V. C. Sheffield, Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma, J. Clin. Invest. 124 (2014) 1956–1965; https://doi.org/10.1172/JCI6977410.1172/JCI69774400153224691439 Search in Google Scholar

46. M. D. Kamitsuka, M. A. Williams, D. A. Nyberg, K. A. Fox, D. L. Lee and D. Hickok, Renal calcification: a complication of dexamethasone therapy in preterm infants with bronchopulmonary dysplasia, J. Perinatol. 15 (1995) 359–363. Search in Google Scholar

47. D. J. Cranefield, D. E. Odd, J. E. Harding and R. L. Teele, High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone, Pediatr. Radiol. 34 (2004) 138–142; https://doi.org/10.1007/s00247-003-1090-710.1007/s00247-003-1090-714624322 Search in Google Scholar

48. K. Gendo, S. D. Sullivan, P. Lozano, J. A. Finkelstein, A. Fuhlbrigge and K. B. Weiss, Resource costs for asthma-related care among pediatric patients in managed care, Ann. Allergy Asthma Immunol. 91(3) (2003) 251–257; https://doi.org/10.1016/S1081-1206(10)63526-010.1016/S1081-1206(10)63526-0 Search in Google Scholar

49. D. C. Perantie and E. S. Brown, Corticosteroids, immune suppression, and psychosis, Curr. Psychiatry Rep. 4 (2002) 171–176; https://doi.org/10.1007/s11920-002-0023-810.1007/s11920-002-0023-812003678 Search in Google Scholar

50. R. Hajjo, D. A. Sabbah and S. K. Bardaweel, Chemocentric informatics analysis: Dexamethasone versus combination therapy for COVID-19, ACS Omega 5(46) (2020) 29765–29779; https://doi.org/10.1021/acsomega.0c0359710.1021/acsomega.0c03597768966233251412 Search in Google Scholar

51. T. Izumo, M. Inomata, N. Kuse, N. Awano, M. Tone, K. Takada, Y. Muto, K. Fujimoto, A. Ueda and M. Hayashi, Combination therapy with remdesivir, dexamethasone, and tocilizumab in patients with severe corona virus disease 2019 in clinical practice, Res. Square - preprint posted 16 Oct, 2020; https://doi.org/10.21203/rs.3.rs-91919/v110.21203/rs.3.rs-91919/v1 Search in Google Scholar

52. P. Baghaei, F. Dastan, M. Marjani, A. Moniri, Z. Abtahian, S. Ghadimi, M. Valizadeh, J. Heshmatnia, M. S. Mirenayat, A. Abedini, A. Kiani, A. Eslaminejad, S. M. Hashemian, H. Jamaati, A. Zali, A. A. Velayati and P. Tabarsi, Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of severe COVID-19 infected inpatients, Int. Immunopharmacol. 92 (2021) Article ID 107329; https://doi.org/10.1016/j.intimp.2020.10732910.1016/j.intimp.2020.107329776280133412395 Search in Google Scholar

53. T. Izumo, N. Kuse, N. Awano, M. Tone, K. Sakamoto, K. Takada, Y. Muto, K. Fujimoto, A. Saiki, Y. Ito, H. Matsumoto and M. Inomata, Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19, Respir. Invest. 59(6) (2021) 799–803; https://doi.org/10.1016/j.resinv.2021.07.00410.1016/j.resinv.2021.07.004835267734413006 Search in Google Scholar

54. J. V. Fahy and B. F. Dickey, Airway mucus function and dysfunction, N. Engl. J. Med. 363 (2010) 2233–2247; https://doi.org/10.1056/NEJMra091006110.1056/NEJMra0910061404873621121836 Search in Google Scholar

55. A. J. Lier, J. J. Tuan, M. W. Davis, N. Paulson, D. McManus, S. Campbell, D. R. Peaper and J. E. Topal, Case report: Disseminated strongyloidiasis in a patient with COVID-19, Am. J. Trop. Med. Hyg. 103(4) (2020) 1590–1592; https://doi.org/10.4269/ajtmh.20-069910.4269/ajtmh.20-0699754380332830642 Search in Google Scholar

56. G. U. Meduri, L. Bridges, M. C. Shih, P. E. Marik, R. C. Siemieniuk and M. Kocak, Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature, Intens. Care Med. 42 (2016) 829–840; https://doi.org/10.1007/s00134-015-4095-410.1007/s00134-015-4095-426508525 Search in Google Scholar

57. A. K. Singh, S. Majumdar, R. Singh and A. Misra, Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective, Diabetes Metab. Syndr. Clin. Res. Rev. 14(5) (2020) 971–978; https://doi.org/10.1016/j.dsx.2020.06.05410.1016/j.dsx.2020.06.054732071332610262 Search in Google Scholar

58. S. A. Amin, K. Ghosh, S. Gayen and T. Jha, Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors, J. Biomol. Struct. Dyn. 39(13) (2021) 4764–4773; https://doi.org/10.1080/07391102.2020.178094610.1080/07391102.2020.1780946 Search in Google Scholar

59. J. J. Condemi, S. Goldstein, C. Kalberg, S. Yancey, A. Emmett and K. Rickard, The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma, Ann. Allergy, Asthma Immunol. 82(4) (1999) 383–389; https://doi.org/10.1016/S1081-1206(10)63288-710.1016/S1081-1206(10)63288-7 Search in Google Scholar

60. A. Woolcock, B. O. Lundback, N. Ringdal and L. A. Jacques, Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids, Am. J. Respir. Crit. Care Med. 153(5) (1996) 1481–1488; https://doi.org/10.1164/ajrccm.153.5.863059010.1164/ajrccm.153.5.86305908630590 Search in Google Scholar

61. J. L. Black, B. G. Oliver and M. Roth, Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting β-agonists, Chest 136(4) (2009) 1095–1100; https://doi.org/10.1378/chest.09-035410.1378/chest.09-035419809050 Search in Google Scholar

62. L. Fuso, N. Mores, S. Valente, M. Malerba and P. Montuschi, Long-acting beta-agonists and their association with inhaled corticosteroids in COPD, Curr. Med. Chem. 20(12) (2013) 1477–1495; https://doi.org/10.2174/092986731132012000310.2174/092986731132012000323409722 Search in Google Scholar

63. L. J. Nannini, P. Poole, S. J. Milan and A. Kesterton, Combined Corticosteroid and Long-Acting Beta2-Agonist in One Inhaler versus Inhaled Corticosteroids Alone for Chronic Obstructive Pulmonary Disease, in: Cochrane Database Systematic Reviews (Issue 8. Art. No.: CD006826), Cochrane Library 2013, Wiley, Hoboken (NJ, USA), 2014; https://doi.org/10.1002/14651858.CD006826.pub210.1002/14651858.CD006826.pub2648627423990350 Search in Google Scholar

64. P. Sinha and B. P. Linas, Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality, Clin. Infect. Dis. 73(11) (2021) 2116–2118; https://doi.org/10.1093/cid/ciab409 Search in Google Scholar

65. D. E. Gordon, G. M. Jang, M. Bouhaddou, J. Xu, K. Obernier, K. M. White, M. J. O’Meara, V. V. Rezelj, J. Z. Guo, D. L. Swaney, T. A. Tummino, R. Hüttenhain, R. M. Kaake, A. L. Richards, B. Tutuncuoglu, H. Foussard, J. Batra, K. Haas, M. Modak, M. Kim, P. Haas, B. J. Polacco, H. Braberg, J. M. Fabius, M. Eckhardt, M. Soucheray, M. J. Bennett, M. Cakir, M.. J. McGregor, Q. Li, B. Meyer, F. Roesch, T. Vallet, A. M. Kain, L. Miorin, E. Moreno, Z. C. Naing, Y. Zhou, S. Peng, Y. Shi, Z. Zhang, W. Shen, I. T. Kirby, J. E. Melnyk, J. S. Chorba, K. Lou, S. A. Dai, I. Barrio-Hernandez, D. Memon, C. Hernandez-Armenta, J. Lyu, C. J. Mathy, T. Perica, K. B. Pilla, S. J. Ganesan, D. J. Saltzberg, R. Rakesh, X. Liu, S. B. Rosenthal, L. Calviello, S. Venkataramanan, J. Liboy-Lugo, Y. Lin, X.-P. Huang, Y. F. Liu, S. A. Wankowicz, M. Bohn, M. Safari, F. S. Ugur, C. Koh, N. S. Savar, Q. D. Tran, D. Shengjuler, S. J. Fletcher, M. C. O’Neal, Y. Cai, J. C. Chang, D. J. Broadhurst, S. Klippsten, P. P. Sharp, N. A. Wenzell, D. Kuzuoglu-Ozturk, H.-Y. Wang, R. Trenker, J. M. Young, D. A. Cavero, J. Hiatt, T. L. Roth, U. Rathore, A. Subramanian, J. Noack, M. Hubert, R. M. Stroud, A. D. Frankel, O. S. Rosenberg, K. A. Verba, D. A. Agard, M. Ott, M. Emerman, N. Jura, M. Zastrow, E. Verdin, A. Ashworth, O. Schwartz, C. Enfert, S. Mukherjee, M. Jacobson, H. S. Malik, D. G. Fujimori, T. Ideker, C. S. Craik, S. N. Floor, J. S. Fraser, J. D. Gross, A. Sali, B. L. Roth, D. Ruggero, J. Taunton, T. Kortemme, P. Beltrao, M. Vignuzzi, A. García-Sastre, K. M. Shokat, B. K. Shoichet and N. J. Krogan, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature 583 (2020) 459–468; https://doi.org/10.1038/s41586-020-2286-910.1038/s41586-020-2286-9743103032353859 Search in Google Scholar

66. Y. Jo, L. Jamieson, I. Edoka, L. Long, S. Silal, J. R. C. Pulliam, H. Moultrie, I. Sanne, G. Meyer-Rath and B. E. Nichols, Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa, Open Forum Inectf. Dis. 8(3) (2021) Article ID ofab040 (8 pages); https://doi.org/10.1093/ofid/ofab04010.1093/ofid/ofab040792862433732750 Search in Google Scholar

67. S. Nile, A. Nile, J. Qiu, L. Lin, X. Jia and G. Kai, COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons, Cytokine Growth Factor Rev. 53 (2020) 66–70; https://doi.org/10.1016/j.cytogfr.2020.05.00210.1016/j.cytogfr.2020.05.002720466932418715 Search in Google Scholar

68. M. H. Ahmed and A. Hassan. Dexamethasone for the treatment of coronavirus disease (COVID-19): a review, SN Compr. Clin. Med. 2 (2020) 2637–2646; https://doi.org/10.1007/s42399-020-00610-810.1007/s42399-020-00610-8759912133163859 Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo